Revolution Medicines, Inc. (Nasdaq: RVMD) announced that Steve Kelsey, M.D., president of research and development, will transition to the role of senior advisor to the chief executive officer effective July 1, 2026, with a planned retirement on January 4, 2027.

Dr. Kelsey has held the president of R&D role since March 2017, overseeing drug discovery and development, translational research, and manufacturing. Upon his retirement, the company said it anticipates appointing him to its board of directors.

As part of the leadership restructuring, also effective July 1, 2026, Alan Sandler, M.D., chief development officer, will continue to oversee the company's development department. Jan Smith, Ph.D., chief scientific officer, will take responsibility for research activities. Xiaolin Wang, Sc.D., will assume the newly created role of executive vice president, integrated portfolio strategy and management, covering portfolio strategy, pharmaceutical development, and manufacturing.

Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D., credited Dr. Kelsey with building the scientific environment that advanced the company's RAS(ON) inhibitor portfolio. "He has embodied our culture of challenging longstanding dogma through bold science, operational discipline and an unwavering commitment to improving outcomes for patients," Goldsmith said in the statement.